Percheron Therapeutics Aktie

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2021, Percheron Therapeutics Aktie has already paid €0.0732 in dividends. The last payout was in July 2021.

Financials

In the last year, Percheron Therapeutics Aktie had revenue of €1.85m and net profit of -€7.41m

(EUR)	2024	YoY
Revenue	1.85m	91.36%
Gross profit	1.81m	99.37%
Net profit	-7.41m	6.68%
EBITDA	-7.4m	6.63%

Fundamentals

Metric	Value
Market capitalization	€17.52m
Number of shares	1.64bn
52-week high/low	€0.0669 - €0.00892
Dividends	No
Beta	0.87
P/E ratio	-
PEG ratio	-
P/B ratio	-
P/S ratio	-

Company profile

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.